|
Volumn 14, Issue 8, 2015, Pages 1047-1049
|
Gardasil 9 joins the fight against cervix cancer
|
Author keywords
9 valent vaccine; cervical disease; Gardasil; human papilloma virus; vaccination
|
Indexed keywords
WART VIRUS VACCINE;
ANTIBODY RESPONSE;
ANTIBODY TITER;
CANCER PREVENTION;
CLINICAL TRIAL (TOPIC);
FEMALE;
GROUPS BY AGE;
HUMAN;
PRIORITY JOURNAL;
REVIEW;
UTERINE CERVIX CANCER;
WART VIRUS;
ADOLESCENT;
ADULT;
ADVERSE DRUG REACTION;
COMPLICATION;
PAPILLOMAVIRUS INFECTION;
TREATMENT OUTCOME;
UTERINE CERVICAL NEOPLASMS;
YOUNG ADULT;
ADOLESCENT;
ADULT;
CLINICAL TRIALS AS TOPIC;
DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS;
FEMALE;
HUMAN PAPILLOMAVIRUS RECOMBINANT VACCINE QUADRIVALENT, TYPES 6, 11, 16, 18;
HUMANS;
PAPILLOMAVIRUS INFECTIONS;
TREATMENT OUTCOME;
UTERINE CERVICAL NEOPLASMS;
YOUNG ADULT;
|
EID: 84937134876
PISSN: 14760584
EISSN: 17448395
Source Type: Journal
DOI: 10.1586/14760584.2015.1051470 Document Type: Review |
Times cited : (41)
|
References (7)
|